COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
NCT05075538 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 152
Last updated 2024-01-17
Summary
This trial aims to measure the humoral and adaptive immune response in patients with cancer diagnosis undergoing mRNA vaccination against SARS-CoV-2 and assess its efficacy in preventing COVID-19.
Conditions
Interventions
- BIOLOGICAL
-
Spikevax
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
- BIOLOGICAL
-
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
- BIOLOGICAL
-
Spikevax bivalent Original/Omicron BA.1
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
- BIOLOGICAL
-
Spikevax bivalent Original/Omicron BA.4-5
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
- BIOLOGICAL
-
Comirnaty Original/Omicron BA.1
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
- BIOLOGICAL
-
Comirnaty Original/Omicron BA.4-5
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
- BIOLOGICAL
-
Comirnaty Omicron XBB.1.5
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
- BIOLOGICAL
-
Spikevax Omicron XBB.1.5
Booster dose, if a booster dose is administered during the study per local / national health policy guidelines.
Sponsors & Collaborators
-
Roche Pharma AG
collaborator INDUSTRY -
Jules Bordet Institute
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-12-01
- Primary Completion
- 2024-01-08
- Completion
- 2024-01-08
Countries
- Belgium
Study Locations
More Related Trials
-
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
NCT04379518 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
NCT04977024 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
NCT05435339 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
NCT03169738 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
NCT03059823 ·Status: COMPLETED ·Phase: PHASE1
-
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
NCT07293754 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
The Immune Reaction Upon COVID-19 Vaccination in the Belgian Cancer Population.
NCT05033158 ·Status: COMPLETED ·Phase: NA
-
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
NCT03175666 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Vaccine Treatment for Advanced Breast Cancer
NCT00090480 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Booster Dose Trial
NCT05016622 ·Status: TERMINATED ·Phase: PHASE2
-
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
NCT00145158 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Effect of Refnot on Immunity in Cancer Patients
NCT05898451 ·Status: COMPLETED ·Phase: PHASE2
-
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
NCT03169764 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
NCT00488592 ·Status: COMPLETED ·Phase: PHASE2
-
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
NCT02706392 ·Status: TERMINATED ·Phase: PHASE1
-
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
NCT00085189 ·Status: COMPLETED ·Phase: PHASE2
-
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
NCT03480152 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission
NCT00227474 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
NCT07317505 ·Status: RECRUITING ·Phase: PHASE1
-
Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma
NCT00145145 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
NCT03387085 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
NCT03387111 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
NCT02054104 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
QUILT-3.088: NANT Pancreatic Cancer Vaccine
NCT03563144 ·Status: WITHDRAWN ·Phase: PHASE2
-
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
NCT03197571 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2